文献速递前列腺增生与排尿功能障碍

全植入式镍尺寸及形状胫神经刺激器治疗膀胱过度活动症伴急迫性尿失禁的可行性

Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.
PubMed 文献 · J Urol · 2019-01-01

这项前瞻性单臂开放标签可行性试验在美国和新西兰多个中心纳入46例难治性急迫性尿失禁患者,植入全植入式原电池供电镍尺寸神经调节装置eCoin®刺激胫神经。激活3个月后急迫性尿失禁发作相对中位数减少71%(每日4.2次 vs 1.7次,p=0.001),69.6%患者发作减少≥50%,3个月和6个月时超过20%患者完全干燥,I-QOL评分平均改善25.9分,72%患者症状改善;1例与伤口护理相关的严重不良事件经静脉抗生素治疗痊愈。结论认为该装置安全有效,无显著安全性担忧。

要点

  • 激活3个月后急迫性尿失禁每日发作相对中位数减少71%(4.2次 vs 1.7次,p=0.001)。
  • 46例中32例(69.6%)在3个月时发作减少≥50%,3和6个月时超过20%患者完全干燥。
  • I-QOL评分平均改善25.9分,46例中33例(72%)报告症状改善;1例严重不良事件经静脉抗生素治愈。

核心结论

  • 全植入式胫神经调节装置是治疗膀胱过度活动症相关急迫性尿失禁的安全有效方法,症状显著减少或缓解且无显著安全性担忧。

研究设计与样本

  • 前瞻性、单臂、开放标签临床可行性试验,在美国和新西兰多个中心纳入46例难治性急迫性尿失禁患者。
  • 装置植入小腿胫神经上方,4周后激活;激活后3个月和6个月收集膀胱日记数据及经验证的生活质量量表,并与基线比较。

主要发现

  • 参与者平均±标准差年龄63.4±11.5岁,45例(98%)为女性。
  • 治疗3个月后急迫性尿失禁发作相对中位数减少71%(每日发作4.2次 vs 1.7次,p=0.001)。
  • 3个月时46例中32例(69.6%)报告急迫性尿失禁发作减少≥50%;3个月和6个月时超过20%患者完全干燥。
  • I-QOL评分平均改善25.9分,46例中33例(72%)报告症状改善。
  • 1例继发于伤口护理的严重不良事件经静脉抗生素治疗痊愈。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We performed a clinical feasibility trial to evaluate the safety and efficacy of a fully implanted, primary battery powered, nickel sized and shaped neuromodulation device called the eCoin® for tibial nerve stimulation to treat refractory urgency urinary incontinence. MATERIALS AND METHODS: This prospective, single arm, open label study included 46 participants with refractory urgency urinary incontinence. It was performed at multiple sites in the United States and New Zealand. The device was implanted in the lower leg over the tibial nerve and activated after 4 weeks. Bladder diary data and validated quality of life instruments were collected 3 and 6 months after activation and compared to baseline values. RESULTS: The mean ± SD age of participants was 63.4 ± 11.5 years and 45 (98%) were female. Episodes of urgency urinary incontinence were reduced a relative median of 71% after 3 months of treatment (4.2 vs 1.7 daily episodes at 3 months, p = 0.001). A 50% or greater decrease in reported episodes of urgency urinary incontinence was observed in 32 of 46 participants (69.6%) at 3 months with more than 20% dry at 3 and 6 months. I-QOL (Incontinence Quality of Life) scores improved an average of 25.9 points and 33 of 46 patients (72%) indicated improvement in symptoms. A single serious adverse event secondary to wound care resolved with intravenous antibiotics. CONCLUSIONS: The implantable neuromodulation device was a safe and effective treatment of urgency urinary incontinence associated with overactive bladder syndrome with a significant reduction or resolution of symptoms and no significant safety concerns.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. MacDiarmid S, Staskin DR, Lucente V, et al. Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence. J Urol. 2019. PMID: 31009968. doi:10.1016/j.juro.2018.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。